Kardigan advances three late-stage cardiovascular trials, reports $660.7M cash

Kardigan reported second quarter 2026 results on August 11, 2026, with updates across its three clinical programs. In July, the company completed enrollment of Cohort 1, covering MYH7 and TTN patients, in the Phase 2b KINSHIP-DCM trial for danicamtiv, and enrollment in the Phase 3 portion is now underway.¹ Kardigan expects to share Phase 2b topline data in the first half of 2027.¹

For ataciguat, the company's sGC activator for calcific aortic valve stenosis, the KATALYST-AV Phase 2b trial is enrolling patients with moderate disease, and the company expects to share Phase 2b topline data from the interim 24-week analysis in the first half of 2027.¹

On tonlamarsen, the antisense oligonucleotide targeting hepatic angiotensinogen for acute severe hypertension, Kardigan randomized the first patient in the KARDINAL-ASH Phase 2 trial during the second quarter and expects to share Phase 2 topline data in the first half of 2027.¹

The company also plans to present preclinical and clinical data on danicamtiv's effect on right ventricular function, and extended follow-up data on tonlamarsen from an earlier KARDINAL trial, at the European Society of Cardiology Congress on August 30, 2026.¹

In June, Kardigan closed its initial public offering with gross proceeds of $460 million before expenses.¹ Cash, cash equivalents and investments totaled $660.7 million as of June 30, 2026, up from $335.5 million at the end of 2025.¹ The company said its current cash runway supports advancement of all three programs through clinical data readouts and the start of Phase 3 trials across the portfolio.¹